Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Fulgent Genetics Q3 2026 Results: Net Loss of $13.2M, Loss Widens

Fulgent Genetics reported a net loss of $13.2 million for Q3 2026 on revenue of $90.4 million, compared to a net loss of $6.6 million on $84.1 million in revenue for the same period in 2025. The company's cash and marketable securities position decreased significantly from $636.0 million at year-end 2025 to $652.3 million as of September 30, 2026, impacted by $64.6 million in common stock repurchases during the first nine months of the year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue90.484.1
Gross profit31.935.5
Profit before tax-14.0-7.5
Net income-13.2-6.6

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+7.5%
Gross margin35.3%
Operating margin-24.9%
Source

10-Q filed with the SEC, NASDAQ: FLGT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Fulgent Genetics, Inc.: key numbers

Share price
$24.21Close, Nov 17
Market cap
$676M
Shares outstanding
27.94MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Fulgent Genetics, Inc.

All →
4:13 PM ET 8-K
Financial Results

Fulgent Genetics Financial Results

Fulgent Genetics reported Q3 2026 revenue of $90.4 million, representing 8% year-over-year growth. The company reported a GAAP loss of $13.2 million and maintained its full-year 2026 revenue guidance of $330 million to $340 million. Management highlighted momentum in their therapeutics pipeline and the integration of AI into laboratory services workflows.

Term
Q3 2026

“We are encouraged by the momentum in our therapeutics pipeline, with both FID-007 and FID-022 using our nano-drug delivery platform. In our laboratory services business, we continue to integrate AI into our workflow as utilization scales and reliability substantially increases. We expect to continue to expand our AI portfolio to drive further improvements to efficiency and quality.”

Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer

“We are pleased with our third quarter results, driven by the improvement in our collection rates. We made great progress to address the billing system issue and remain confident in our outlook for the remainder of the year.”

Paul Kim, Chief Financial Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.